Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > mBC researcher self-treated with OV now recurrent free
View:
Post by Noteable on Oct 19, 2024 9:36pm

mBC researcher self-treated with OV now recurrent free

https://www.researchgate.net/publication/383452102_An_Unconventional_Case_Study_of_Neoadjuvant_Oncolytic_Virotherapy_for_Recurrent_Breast_Cancer
Comment by Noteable on Oct 19, 2024 9:41pm
The August 2024 reporting concluded that :  'Although an isolated case, it encourages consideration of oncolytic virotherapy as a neoadjuvant treatment modality.'
Comment by Noteable on Oct 19, 2024 9:53pm
This unconventional case finding further confirms ONCY's Phase 2 Bracelet-1 mBC study involving the intravenous administration of pelareorep (monotherapy) + paclitaxel as an effective combination therapy for the treatment of metastatic breast cancer. The addition of a Fc attenuated PD-(L)1 immune checkpoint inhibitor to the pelareorep + paclitaxel combination would have an enhance positive ...more  
Oncolytics Biotech Inc